Smad7 Modulates Epidermal Growth Factor Receptor Turnover through Sequestration of c-Cbl

REFERENCES

• Derynck R, Akhurst RJ. 2007. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol 9:1000–1004. http://dx.doi.org/10.1038/ncb434.
   PubMed Web of Science ®Google Scholar
• Massagué J. 2008. TGFβ in Cancer Cell 134:215–230. http://dx.doi.org/10.1016/j.cell.2008.07.001.
   Google Scholar
• Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P. 1997. Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling. Nature 389:631–635. http://dx.doi.org/10.1038/39369.
   PubMed Web of Science ®Google Scholar
• Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. 2001. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276:12477–12480. http://dx.doi.org/10.1074/jbc.C100008200.
   PubMed Web of Science ®Google Scholar
• Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y, Han Y, Feng X-H, Meng A, Chen Y-G. 2007. Smad7 antagonizes transforming growth factor beta signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol 27:4488–4499. http://dx.doi.org/10.1128/MCB.01636-06.
   PubMed Web of Science ®Google Scholar
• Javelaud D, Mohammad KS, McKenna CR, Fournier P, Luciani F, Niewolna M, André J, Delmas V, Larue L, Guise TA, Mauviel A. 2007. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 67:2317–2324. http://dx.doi.org/10.1158/0008-5472.CAN-06-3950.
   PubMed Web of Science ®Google Scholar
• Kim YH, Lee HS, Lee H-J, Hur K, Kim WH, Bang Y-J, Kim S-J, Lee KU, Choe KJ, Yang H-K. 2004. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol Off J Eur Soc Med Oncol ESMO 15:574–580. http://dx.doi.org/10.1093/annonc/mdh131.
   PubMedGoogle Scholar
• Wang J, Zhao J, Chu ESH, Mok MTS, Go MYY, Man K, Heuchel R, Lan HY, Chang Z, Sung JJY, Yu J. 2013. Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro. J Pathol 230:441–452. http://dx.doi.org/10.1002/path.4206.
   PubMed Web of Science ®Google Scholar
• Liu X, Lee J, Cooley M, Bhogte E, Hartley S, Glick A. 2003. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 63:7760–7768.
   PubMed Web of Science ®Google Scholar
• Fry WHD, Kotelawala L, Sweeney C, Carraway KL. 2009. Mechanisms of ErbB receptor negative regulation and relevance in cancer. Exp Cell Res 315:697–706. http://dx.doi.org/10.1016/j.yexcr.2008.07.022.
   PubMedGoogle Scholar
• Di Fiore PP, Gill GN. 1999. Endocytosis and mitogenic signaling. Curr Opin Cell Biol 11:483–488. http://dx.doi.org/10.1016/S0955-0674(99)80069-6.
   PubMedGoogle Scholar
• de Melker AA, van der Horst G, Calafat J, Jansen H, Borst J. 2001. c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route. J Cell Sci 114:2167–2178.
   PubMedGoogle Scholar
• Duan L, Miura Y, Dimri M, Majumder B, Dodge IL, Reddi AL, Ghosh A, Fernandes N, Zhou P, Mullane-Robinson K, Rao N, Donoghue S, Rogers RA, Bowtell D, Naramura M, Gu H, Band V, Band H. 2003. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 278:28950–28960. http://dx.doi.org/10.1074/jbc.M304474200.
   PubMed Web of Science ®Google Scholar
• Fukazawa T, Miyake S, Band V, Band H. 1996. Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem 271:14554–14559. http://dx.doi.org/10.1074/jbc.271.24.14554.
   PubMed Web of Science ®Google Scholar
• Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. 1999. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286:309–312. http://dx.doi.org/10.1126/science.286.5438.309.
   PubMed Web of Science ®Google Scholar
• Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY, Beguinot L, Geiger B, Yarden Y. 1998. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 12:3663–3674. http://dx.doi.org/10.1101/gad.12.23.3663.
   PubMed Web of Science ®Google Scholar
• Fujikawa K, de Aos Scherpenseel I, Jain SK, Presman E, Christensen RA, Varticovski L. 1999. Role of PI 3-kinase in angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp Cell Res 253:663–672. http://dx.doi.org/10.1006/excr.1999.4693.
   PubMed Web of Science ®Google Scholar
• Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, Zhang H, Yoshimura A, Baron R. 1999. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem 274:31707–31712. http://dx.doi.org/10.1074/jbc.274.44.31707.
   PubMed Web of Science ®Google Scholar
• Lee YS, Park JS, Kim JH, Jung SM, Lee JY, Kim S-J, Park SH. 2011. Smad6-specific recruitment of Smurf E3 ligases mediates TGF-β1-induced degradation of MyD88 in TLR4 signalling. Nat Commun 2:460. http://dx.doi.org/10.1038/ncomms1469.
   PubMed Web of Science ®Google Scholar
• He W, Li AG, Wang D, Han S, Zheng B, Goumans M-J, ten Dijke P, Wang X-J. 2002. Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. EMBO J 21:2580–2590. http://dx.doi.org/10.1093/emboj/21.11.2580.
   PubMed Web of Science ®Google Scholar
• Hong S, Lim S, Li AG, Lee C, Lee YS, Lee E-K, Park SH, Wang X-J, Kim S-J. 2007. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat Immunol 8:504–513. http://dx.doi.org/10.1038/ni1451.
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Li C, Wheeler DL. 2011. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 12:419–432.
   PubMed Web of Science ®Google Scholar
• Schlessinger J. 2002. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110:669–672. http://dx.doi.org/10.1016/S0092-8674(02)00966-2.
   PubMed Web of Science ®Google Scholar
• Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, Lipkowitz S, Yarden Y. 1999. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4:1029–1040. http://dx.doi.org/10.1016/S1097-2765(00)80231-2.
   PubMed Web of Science ®Google Scholar
• Javadi M, Richmond TD, Huang K, Barber DL. 2013. CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN. J Biol Chem 288:19459–19470. http://dx.doi.org/10.1074/jbc.M113.475087.
   PubMed Web of Science ®Google Scholar
• Martinelli S, De Luca A, Stellacci E, Rossi C, Checquolo S, Lepri F, Caputo V, Silvano M, Buscherini F, Consoli F, Ferrara G, Digilio MC, Cavaliere ML, van Hagen JM, Zampino G, van der Burgt I, Ferrero GB, Mazzanti L, Screpanti I, Yntema HG, Nillesen WM, Savarirayan R, Zenker M, Dallapiccola B, Gelb BD, Tartaglia M. 2010. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet 87:250–257. http://dx.doi.org/10.1016/j.ajhg.2010.06.015.
   PubMed Web of Science ®Google Scholar
• Sanada M, Suzuki T, Shih L-Y, Otsu M, Kato M, Yamazaki S, Tamura A, Honda H, Sakata-Yanagimoto M, Kumano K, Oda H, Yamagata T, Takita J, Gotoh N, Nakazaki K, Kawamata N, Onodera M, Nobuyoshi M, Hayashi Y, Harada H, Kurokawa M, Chiba S, Mori H, Ozawa K, Omine M, Hirai H, Nakauchi H, Koeffler HP, Ogawa S. 2009. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460:904–908. http://dx.doi.org/10.1038/nature08240.
   PubMed Web of Science ®Google Scholar
• Lupher ML, Songyang Z, Shoelson SE, Cantley LC, Band H. 1997. The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and binds to the Tyr292 negative regulatory phosphorylation site of ZAP-70. J Biol Chem 272:33140–33144. http://dx.doi.org/10.1074/jbc.272.52.33140.
   PubMedGoogle Scholar
• Xian W, Rosenberg MP, DiGiovanni J. 1997. Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. Oncogene 14:1435–1444. http://dx.doi.org/10.1038/sj.onc.1200980.
   PubMedGoogle Scholar
• Rao N, Dodge I, Band H. 2002. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 71:753–763.
   PubMed Web of Science ®Google Scholar
• Margolis BL, Lax I, Kris R, Dombalagian M, Honegger AM, Howk R, Givol D, Ullrich A, Schlessinger J. 1989. All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem 264:10667–10671.
   PubMed Web of Science ®Google Scholar
• Grøvdal LM, Stang E, Sorkin A, Madshus IH. 2004. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 300:388–395. http://dx.doi.org/10.1016/j.yexcr.2004.07.003.
   PubMed Web of Science ®Google Scholar
• Swaminathan G, Tsygankov AY. 2006. The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 209:21–43. http://dx.doi.org/10.1002/jcp.20694.
   PubMed Web of Science ®Google Scholar
• Thien CBF, Langdon WY. 2005. Negative regulation of PTK signalling by Cbl proteins. Growth Factors Chur Switz 23:161–167. http://dx.doi.org/10.1080/08977190500153763.
   PubMed Web of Science ®Google Scholar